ANIP Ani Pharmaceuticals Inc

Price (delayed)

$61.32

Market cap

$1.29B

P/E Ratio

37.85

Dividend/share

N/A

EPS

$1.62

Enterprise value

$1.34B

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), ...

Highlights
The company's EPS has surged by 194% YoY and by 88% QoQ
Ani Pharmaceuticals's net income has surged by 89% QoQ

Key stats

What are the main financial stats of ANIP
Market
Shares outstanding
20.97M
Market cap
$1.29B
Enterprise value
$1.34B
Valuations
Price to book (P/B)
2.86
Price to sales (P/S)
2.3
EV/EBIT
20.08
EV/EBITDA
10.47
EV/Sales
2.6
Earnings
Revenue
$517.46M
EBIT
$66.89M
EBITDA
$128.31M
Free cash flow
$118.22M
Per share
EPS
$1.62
Free cash flow per share
$6.09
Book value per share
$21.44
Revenue per share
$26.64
TBVPS
$35.54
Balance sheet
Total assets
$914.52M
Total liabilities
$437.71M
Debt
$285.46M
Equity
$451.96M
Working capital
$403.67M
Liquidity
Debt to equity
0.63
Current ratio
3.95
Quick ratio
3
Net debt/EBITDA
0.44
Margins
EBITDA margin
24.8%
Gross margin
62.7%
Net margin
6.9%
Operating margin
11.2%
Efficiency
Return on assets
3.8%
Return on equity
7.9%
Return on invested capital
11.2%
Return on capital employed
8.6%
Return on sales
12.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
1.59%
1 week
-0.18%
1 month
-6.28%
1 year
31.42%
YTD
11.21%
QTD
-11.3%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$517.46M
Gross profit
$324.5M
Operating income
$57.82M
Net income
$35.55M
Gross margin
62.7%
Net margin
6.9%
The net margin has soared by 195% YoY and by 77% QoQ
Ani Pharmaceuticals's net income has surged by 89% QoQ
The gross profit has grown by 50% year-on-year and by 6% since the previous quarter
Ani Pharmaceuticals's revenue has increased by 44% YoY and by 6% from the previous quarter

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
P/E
37.85
P/B
2.86
P/S
2.3
EV/EBIT
20.08
EV/EBITDA
10.47
EV/Sales
2.6
The company's EPS has surged by 194% YoY and by 88% QoQ
The company's equity rose by 44% YoY and by 4.4% QoQ
The P/B is 14% above the 5-year quarterly average of 2.5 and 6% above the last 4 quarters average of 2.7
Ani Pharmaceuticals's revenue has increased by 44% YoY and by 6% from the previous quarter
The price to sales (P/S) is 4.2% lower than the 5-year quarterly average of 2.4 and 4.2% lower than the last 4 quarters average of 2.4

Efficiency

How efficient is Ani Pharmaceuticals business performance
The return on equity has surged by 189% year-on-year and by 84% since the previous quarter
The ROA has soared by 90% from the previous quarter
Ani Pharmaceuticals's ROIC has increased by 42% from the previous quarter
The company's return on sales rose by 34% QoQ

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 109% more than its total liabilities
ANIP's quick ratio has surged by 55% year-on-year and by 14% since the previous quarter
The company's current ratio rose by 36% YoY and by 11% QoQ
The debt is 37% lower than the equity
The company's equity rose by 44% YoY and by 4.4% QoQ
The debt to equity has decreased by 31% YoY and by 4.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.